Rob Perez is a biopharmaceutical operating executive with more than 25 years of experience in the industry. Rob is currently serving as an Operating Partner at General Atlantic, providing strategic support and advice to the firm’s investment team and portfolio companies with a particular focus on the biopharma and life sciences sector. Rob is the founder and Chairman of Life Science Cares, co-founder of BLOC, Biopharma Leaders of Color as well as the Executive Chairman of Akili Interactive Labs, Inc..
Previously, he was the Chief Executive Officer of Cubist Pharmaceuticals, Inc., a public pharmaceutical development company, when the company was acquired by Merck in January 2015. He joined Cubist in August 2003 as Senior Vice President, Sales and Marketing, and led the launch of Cubicin® (daptomycin for injection).
He also served as Executive Vice President and Chief Operating Officer, and President prior to becoming CEO. Before joining Cubist, he served as Vice President of Biogen, Inc.’s US CNS business unit, where he was responsible for commercial leadership of an $800 million business. He joined Biogen in 1995 and was one of the architects of the commercial model that launched the company’s first commercial product, AVONEX®.
Prior to Biogen, Mr. Perez held various sales and marketing positions at Zeneca Pharmaceuticals. Mr. Perez currently serves as a member of the board of directors for Vir Biotechnology, Path AI, Inc., Third Harmonic Bio and Immunocore Ltd. Mr. Perez is also a member of the Board of Trustees at The Dana Farber Cancer Institute, Inc.
Mr. Perez received a B.S. in business from California State University, Los Angeles and an M.B.A. from the Anderson Graduate School of Management at the University of California, Los Angeles.
Previously, he was the Chief Executive Officer of Cubist Pharmaceuticals, Inc., a public pharmaceutical development company, when the company was acquired by Merck in January 2015. He joined Cubist in August 2003 as Senior Vice President, Sales and Marketing, and led the launch of Cubicin® (daptomycin for injection).
He also served as Executive Vice President and Chief Operating Officer, and President prior to becoming CEO. Before joining Cubist, he served as Vice President of Biogen, Inc.’s US CNS business unit, where he was responsible for commercial leadership of an $800 million business. He joined Biogen in 1995 and was one of the architects of the commercial model that launched the company’s first commercial product, AVONEX®.
Prior to Biogen, Mr. Perez held various sales and marketing positions at Zeneca Pharmaceuticals. Mr. Perez currently serves as a member of the board of directors for Vir Biotechnology, Path AI, Inc., Third Harmonic Bio and Immunocore Ltd. Mr. Perez is also a member of the Board of Trustees at The Dana Farber Cancer Institute, Inc.
Mr. Perez received a B.S. in business from California State University, Los Angeles and an M.B.A. from the Anderson Graduate School of Management at the University of California, Los Angeles.
Speaking In
1:45 PM - 2:45 PM (PDT)
Wednesday, June 15
Executives can ignite change in the biotechnology ecosystem through strategic funding and company…
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
